Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists

ACS Chemical Neuroscience

Volumn 2, Issue 7, 2011, Pages 352-362

  Layton, Mark E ^a   Kelly, Michael J ^a   Rodzinak, Kevin J ^a   Sanderson, Philip E ^a   Young, Steven D ^a   Bednar, Rodney A ^a   Dilella, Anthony G ^a   McDonald, Terrence P ^a   Wang, Hao ^a   Mosser, Scott D ^a   Fay, John F ^a   Cunningham, Michael E ^a   Reiss, Duane R ^a   Fandozzi, Christine ^a   Trainor, Nicole ^a   Liang, Annie ^a   Lis, Edward V ^a   Seabrook, Guy R ^a   Urban, Mark O ^a   Yergey, James ^a   Koblan, Kenneth S ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

neuropathic pain; NMDA; NR2B antagonist; Parkinsons disease

Indexed keywords

1,2,4 OXADIAZOLE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MEGADOSE; DRUG POTENCY; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SPINAL NERVE; SUBSTITUTION REACTION;

ADMINISTRATION, ORAL; ANIMALS; BENZOPYRANS; BIOLOGICAL AVAILABILITY; CATALEPSY; CYCLOPENTANES; DOGS; DRUG DISCOVERY; ETHER-A-GO-GO POTASSIUM CHANNELS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HALF-LIFE; INDICATORS AND REAGENTS; ISOMERISM; LIGATION; MACACA MULATTA; MALE; NEURALGIA; OXADIAZOLES; PARKINSON DISEASE; PIPERIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SPINAL NERVES;

RATTUS;

EID: 79960712880     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn200013d     Document Type: Article

References (57)

1. Dingledine, R., Borges, K., Bowie, D., and Traynelis, S. F. (1999) The Glutamate Receptor Ion Channels Pharmacol. Rev. 51 (1) 7-61 (Pubitemid 29113865)
2. Banke, T. G. and Traynelis, S. F. (2003) Activation of NR1/NR2B NMDA Receptors Nat. Neurosci. 6 (2) 144-152 (Pubitemid 36182783)
3. Le, D. A. and Lipton, S. A. (2001) Potential and Current Use of N -Methyl- d -Aspartate (NMDA) Receptor Antagonists in Diseases of Aging Drugs Aging 18 (10) 717-724 (Pubitemid 33135194)
4. Parsons, C. G., Danysz, W., and Quack, G. (1998) Glutamate in CNS Disorders as a Target for Drug Development: An Update Drug News Perspect. 11 (9) 523-579
5. Kemp, J. A. and McKernan, R. M. (2002) NMDA receptor pathways as drug targets Nat. Neurosci. 5 (suppl.) 1039-1042 (Pubitemid 35247194)
6. Hallett, P. J. and Standaert, D. G. (2004) Rationale for and use of NMDA receptor antagonists in Parkinsons disease Pharmacol. Ther. 102, 155-174 (Pubitemid 38681014)
7. Marino, M. J., Valenti, O., and Conn, P. J. (2003) Glutamate Receptors and Parkinsons Disease: Opportunities for Intervention Drugs Aging 20 (5) 377-397 (Pubitemid 36520959)
8. Hallett, P. J., Dunah, A. W., Ravenscroft, P., Zhou, S., Bezard, E., Crossman, A. R., Brotchie, J. M., and Sandaert, D. G. (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinsons disease Neuropharmacology 48, 503-516 (Pubitemid 40332408)
9. Parsons, C. G. (2001) NMDA receptors as targets for drug action in neuropathic pain Eur. J. Pharmacol. 429, 71-78 (Pubitemid 33043983)
10. Petrenko, A. B., Yamakura, T., Baba, H., and Shimoji, K. (2003) The Role of N-methyl- d -aspartate (NMDA) Receptors in Pain: A Review Anesth. Analg. 97 (4) 1108-1116 (Pubitemid 37158698)
11. Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., and Modius, H. J. (2003) Memantine in Moderate-to-Severe Alzheimers Disease N. Engl. J. Med. 348, 1333-1341
12. Witt, A., Macdonald, N., and Kirkpatrick, P. (2004) Memantine hydrochloride Nat. Rev. Drug Discovery 3 (2) 109-110 (Pubitemid 38239767)
13. Hocking, G. and Cousins, M. J. (2003) Ketamine in chronic pain management: an evidence-based review Anesth. Analg. 97 (6) 1730-1739 (Pubitemid 37475130)
14. McBain, C. J. and Mayer, M. L. (1994) N-Methyl- d -Aspartic Acid Receptor Structure and Function Physiol. Rev. 74 (3) 723-760
15. Bendel, O., Meijer, B., Hurd, Y., and Von Euler, G. (2005) Cloning and expression of the human NMDA receptor subunit NR3B in the adult human hippocampus Neurosci. Lett. 377, 31-36 (Pubitemid 40255634)
16. Chatterton, J. E., Awobuluyl, M., Premkumar, L. S., Takahashi, H., Talantova, M., Shin, Y., Cui, J., Tu, S., Sevarino, K. A., Nakanishi, N., Tong, G., Lipton, S. A., and Zhang, D. (2002) Excitatory glycine receptor containing the NR3 family of NMDA receptor subunits Nature (London) 415 (6873) 793-798 (Pubitemid 34150501)
17. Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., and Seeburg, P. H. (1994) Developmental and Regional Expression in the Rat Brain and Functional Properties of Four NMDA Receptors Neuron 12, 529-540 (Pubitemid 24100885)
18. Lynch, D. R. and Guttman, R. P. (2001) NMDA Receptor Pharmacology: Perspectives from Molecular Biology Curr. Drug Targets 2 (3) 215-231 (Pubitemid 32821467)
19. Erreger, K., Dravid, S. M., Banke, T. G., Wyllie, D. J. A., and Traynelis, S. F. (2005) Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signaling profiles J. Physiol. 563 (2) 345-358 (Pubitemid 40360896)
20. Loftis, J. M. and Janowsky, A. (2003) The N-methyl- d -aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications Pharmacol. Ther. 97 (1) 55-85 (Pubitemid 35477804)
21. Boyce, S., Wyatt, A., Webb, J. K., ODonnell, R., Mason, G., Rigby, M., Sirinathsinghji, D., Hill, R. G., and Rupniak, N. M. J. (1999) Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn Neuropharmacology 38, 611-623 (Pubitemid 29150316)
22. Chazot, P. L. (2004) The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies Curr. Med. Chem. 11 (3) 389-396 (Pubitemid 38240214)
23. Higgins, G. A., Ballard, T. M., Huwyler, J., Kemp, J. A., and Gill, R. (2003) Evaluation of the NR2B-selective NMDA receptor antagonist Ro-63-1908 on rodent behavior: evidence for an involvement of NR2B NMDA receptors in response inhibition Neuropharmacology 44 (3) 324-341 (Pubitemid 36246488)
24. Chizh, B. A., Headley, P. M., and Tzschentke, T. M. (2001) NMDA Receptor Antagonists as Analgesics: Focus on the NR2B Subtype Trends Pharmacol. Sci. 22 (12) 636-642 (Pubitemid 33135525)
25. Williams, K. (2001) Ifenprodil, a Novel NMDA Receptor Antagonist: Site and Mechanism of Action Curr. Drug Targets 2, 285-298 (Pubitemid 32821471)
26. Chenard, B. L., Bordner, J., Butler, T. W., Chambers, L. K., Collins, M. A., De Costa, D. L., Ducat, M. F., Dumont, M. L., Fox, C. B., Mena, E. E., Menniti, F. S., Nielsen, J., Pagnozzi, M. J., Richter, K. E. G., Ronau, R. T., Shalaby, I. A., Stemple, J. Z., and White, W. F. (1995) (1 S,2 S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroprotectant Which Blocks N -Methyl- d -Aspartate Responses J. Med. Chem. 38 (16) 3138-3145
27. Doyle, K. M., Feerick, S., Kirby, D. L., Eddleston, A., and Higgins, G. A. (1998) Comparison of various N-methyl- d -aspartate receptor antagonists in a model of short-term memory and on overt behavior Behav. Pharmacol. 9 (8) 671-681 (Pubitemid 29017620)
28. Guscott, M. R., Clarke, H. F., Murray, F., Grimwood, S., Bristow, L. J., and Hutson, P. H. (2003) The effect of CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze Eur. J. Pharmacol. 476 (3) 193-199 (Pubitemid 37272147)
29. Kundrotiene, J., Cebers, G., Wagner, A., and Liljequist, S. (2004) The NMDA NR2B Subunit-Selective Receptor Antagonist, CP-101,606, Enhances the Functional Recovery and Reduces Brain Damage after Cortical Compression-Induced Brain Ischemia J. Neurotrauma 21 (1) 83-93 (Pubitemid 38141805)
30. Tanaguchi, K., Shinjo, K., Mizutani, M., Shimada, K., Ishikawa, T., Menniti, F. S., and Nagahishi, A. (1997) Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist Br. J. Pharmacol. 122 (5) 809-812 (Pubitemid 27460160)
31. Nash, J. E. and Brotchie, J. M. (2002) Characterisation of Striatal NMDA Receptors Involved in the Generation of Parkinsonian Symptoms: Intrastrial Microinjection Studies in the 6-OHDA-Lesioned Rat Mov. Disord. 17 (3) 455-466 (Pubitemid 36040956)
32. Wessell, R. H., Ahmed, S. M., Menniti, F. S., Dunbar, G. L., Chase, T. N., and Oh, J. D. (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats Neuropharmacology 47, 184-194 (Pubitemid 38824642)
33. Steece-Collier, K., Chambers, L. K., Jaw-Tsai, S. S., Menniti, F. S., and Greenamyre, J. T. (2000) Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl- d -Aspartate Receptors Exp. Neurol. 163 (1) 239-243 (Pubitemid 30314379)
34. Merchant, R. E., Bullock, M. R., Carmack, C. A., Shah, A. K., Wilner, K. D., Ko, G., and Williams, S. A. (1999) A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury Ann. N.Y. Acad. Sci. 890, 42-50 (Pubitemid 30040363)
35. Bullock, R. M., Merchant, R. E., Carmack, C. A., Doppenberg, E., Shah, A. K., Wilner, K. D., Ko, G., and Williams, S. A. (1999) An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage Ann. N.Y. Acad. Sci. 890, 51-58 (Pubitemid 30040364)
36. Sang, C. N., Weaver, J. J., Jinga, L., Wouden, J., and Saltarelli, M. D. (2003) The NR2B subunit-selective NMDA receptor antagonist, CP-101,606, reduces spontaneous pain intensity in patients with central and peripheral neuropathic pain Soc. Neurosci. Abstr. 814, 9
37. Layton, M. E., Kelly, M. J., and Rodzinak, K. J. (2006) Recent Advances in the Development of NR2B Subtype-selective NMDA Receptor Antagonists Curr. Top. Med. Chem. 6, 697-709
38. McCauley, J. A. (2005) NR2B subtype-selective NMDA receptor antagonists: 2001-2004 Expert Opin. Ther. Pat. 15 (4) 389-407 (Pubitemid 40613895)
39. Fischer, G., Mutel, V., Trube, G., Malherbe, P., Key, J. N. C., Mohacsi, E., Heitz, M. P., and Kemp, J. A. (1997) Ro 25-6981, a highly potent and selective blocker of N-methyl- d -aspartate receptors containing the NR2B subunit. Characterization in vitro J. Pharm. Exp. Ther. 283, 1285-1292 (Pubitemid 28016504)
40. Pinard, E., Alanine, A., Bourson, A., Buttelmann, B., Heitz, M.-P., Mutel, V., Gill, R., Trube, G., and Wyler, R. (2002) 4-Aminoquinolines as a Novel Class of NR1/2B Subtype Selective NMDA Receptor Antagonists Bioorg. Med. Chem. Lett. 12, 2615-2619 (Pubitemid 35245294)
41. Claiborne, C. F., McCauley, J. A., Libby, B. E., Curtis, N. R., Diggle, H. J., Kulagowski, J. J, Michelson, S. R., Anderson, K. D., Claremon, D. A., Freidinger, R. M., Bednar, R. A., Mosser, S. D., Gaul, S. L., Connolly, T. M., Condra, C. L., Bednar, B., Stump, G. L., Lynch, J. J., Macaulay, A., Wafford, K. A., Koblan, K. S., and Liverton, N. J. (2003) Orally Efficacious NR2B-Selective NMDA Receptor Antagonists Bioorg. Med. Chem. Lett. 13, 697-700 (Pubitemid 36298471)
42. Nguyen, K. T., Claiborne, C. F., McCauley, J. A., Libby, B. E., Claremon, D. A., Bednar, R. A., Mosser, S. D., Gaul, S. L., Connolly, T. M., Condra, C. L., Bednar, B., Stump, G. L., Lynch, J. J., Koblan, K. S., and Liverton, N. J. (2007) Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists Bioorg. Med. Chem. Lett. 17, 3997-4000 (Pubitemid 46920928)
43. Liverton, N. J., Bednar, R. A., Bednar, B., Butcher, J. W., Claiborne, C. F., Claremon, D. A., Cunningham, M., DiLella, A. G., Gaul, S. L., Libby, B. E., Lyle, E. A., Lynch, J. J., McCauley, J. A., Mosser, S. D., Nguyen, K. T., Stump, G. L., Sun, H., Wang, H., Yergey, J., and Koblan, K. S. (2007) Identification and Characterization of 4-Methylbenzyl 4-[(Pyrimidin-2-ylamino) methyl]piperidine-1-carboxylate, an Orally Bioavailable, Brain Penetrant NR2B Selective N-Methyl- d -Aspartate Receptor Antagonist J. Med. Chem. 50, 807-819 (Pubitemid 46332992)
44. Liverton, N. J., Butcher, J. W., McIntyre, C. J., Claiborne, C. F., Claremon, D. A., McCauley, J. A., Romano, J. J., Thompson, W., and Munson, P. M. Preparation of N-substituted nonaryl heterocyclyl amides as NMDA/NR2B antagonists for relieving pain. PCT Int. Appl. WO 2002080928 A1, 17 October 2002.
45. Thompson, W., Young, S. D., Phillips, B. T., Munson, P., Whitter, W., Liverton, N., Dieckhaus, C., Butcher, J., McCauley, J. A., McIntyre, C. J., Layton, M. E., and Sanderson, P. E. Preparation of 4- Cycloalkylaminopyrazolopyrimidines as NMDA/NR2B Antagonists. PCT Int. Appl. WO 2005019221 A1, 3 March 2005.
46. Yamazaki, M, Neway, W. E., Ohe, T, I-wu Chen, Rowe, J. F., Hochman, J. H., Chiba, M., and Lin, J. H. (2001) In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results J. Pharmacol. Exp. Ther. 296, 723-735 (Pubitemid 32187340)
47. Kiss, L., Cheng, G., Bednar, B., Bednar, R., Bennett, P., Kane, S. A., McIntyre, C. J., McCauley, J. A., and Koblan, K. S. (2005) In vitro characterization of novel NR2B selective NMDA receptor antagonists Neurochem. Int. 46, 453-464 (Pubitemid 40349593)
48. Butcher, J. W., Claremon, D. A., Connolly, T. M., Dean, D. C., Karczewski, J., Koblan, K. S., Kostura, M. J., Liverton, N. J., and Melillo, D. G. Radioligand and Binding Assay. PCT Int. Appl. WO 0205860 A1, 24 January 2002.
49. Mahar Doan, K. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Sampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., and Polli, J. W. (2002) Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs J. Pharm. Exp. Ther. 303, 1029-1037 (Pubitemid 35424386)
50. Greengrass, P. and Bremner, R. (1979) Binding Characteristics of Prazosin-H-3 to Rat-Brain Alpha-Adrenergic Receptors Eur. J. Pharmacol. 55, 323-326 (Pubitemid 9232801)
51. All animal studies described in this report were approved by the Merck Research Laboratories Institutional Animal Care and Use Committee.
52. Kim, S. H. and Chung, J. M. (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat Pain 50, 355-363
53. %MPE = [(post-treatment value) - (pretreatment value)]/[(preoperation cutoff value) - pretreatment value)].
54. Valenti, O., Marino, M. J., Wittmann, M., Lis, E., DiLella, A. G., Kinney, G. G., and Conn, P. J. (2003) Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse J. Neurosci. 23 (18) 7218-7226 (Pubitemid 36975886)
55. Hamze, A., Hernandez, J.-F., Fulcrand, P., and Martinez, J. (2003) Synthesis of Various 3-Substituted 1,2,4-Oxadiazole-Containing Chiral β3- and α-Amino Acids from Fmoc-Protected Aspartic Acid J. Org. Chem. 68 (19) 7316-7321 (Pubitemid 37122480)
56. McCauley, J. A., Theberge, C. R., Liverton, N. J., Claremon, D. A., and Claiborne, C. F. 2-Benzyl and 2-Heteroaryl Benzimidazole NMDA/NR2B Antagonists. U.S. Patent 6,316,474 B1, Nov. 13, 2001.
57. Bednar, B., Cunningham, M. E., Kiss, L., Cheng, G., McCauley, J. A., Liverton, N. J., and Koblan, K. S. (2004) Kinetic characterization of novel NR2B antagonists using fluorescence detection of calcium flux J. Neurosci. Methods 137, 247-255 (Pubitemid 38942888)